Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease
2007

Serum IL-15 as a Marker for Lung Disease in Systemic Sclerosis

Sample size: 63 publication 10 minutes Evidence: moderate

Author Information

Author(s): Wuttge Dirk M, Wildt Marie, Geborek Pierre, Wollheim Frank A, Scheja Agneta, Ã…kesson Anita

Primary Institution: Department of Rheumatology, Lund University Hospital

Hypothesis

IL-15 levels in the circulation of patients with early systemic sclerosis are associated with vasculopathy and fibrosis.

Conclusion

Increased serum IL-15 levels are associated with fibrotic and vascular lung disease in early systemic sclerosis.

Supporting Evidence

  • Serum IL-15 levels were increased in SSc patients compared to healthy controls.
  • IL-15 levels correlated with impaired lung function.
  • Patients with intermediate IL-15 levels had a higher prevalence of increased systolic pulmonary pressure.

Takeaway

This study found that higher levels of a substance called IL-15 in the blood might help doctors understand lung problems in patients with a disease called systemic sclerosis.

Methodology

Serum IL-15 levels were analyzed in 63 patients with early systemic sclerosis and compared to 33 healthy controls.

Potential Biases

Potential bias due to the exclusion of patients with renal crisis from the analysis.

Limitations

The study only included patients with early systemic sclerosis and may not apply to all patients with the disease.

Participant Demographics

63 patients (51 women, 12 men) with a median age of 54 years.

Statistical Information

P-Value

p<0.01

Confidence Interval

0.47 to 0.88 pg/ml

Statistical Significance

p<0.01

Digital Object Identifier (DOI)

10.1186/ar2284

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication